The licorice root derived isoflavan glabridin increases the function of osteoblastic MC3T3-E1 cells
Glabridin, an isoflavan purified from licorice root, exhibits diverse biological activities, including estrogen-like activity. To investigate the bioactivities of glabridin, which act on bone metabolism, the effects of glabridin on the function of mouse osteoblastic cell line (MC3T3-E1) and the prod...
Saved in:
Published in | Biochemical pharmacology Vol. 70; no. 3; pp. 363 - 368 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.08.2005
Elsevier Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Glabridin, an isoflavan purified from licorice root, exhibits diverse biological activities, including estrogen-like activity. To investigate the bioactivities of glabridin, which act on bone metabolism, the effects of glabridin on the function of mouse osteoblastic cell line (MC3T3-E1) and the production of local factors in osteoblasts were studied. Glabridin (1–10
μM) significantly increased the growth of MC3T3-E1 cells and caused a significant elevation of alkaline phosphatase (ALP) activity, collagen content and osteocalcin secretion in the cells (
P
<
0.05). The effect of glabridin (10
μM) in increasing ALP activity and collagen content was completely prevented by the presence of 10
−6
M cycloheximide and 10
−6
M tamoxifen, suggesting that glabridin's effect results from a newly synthesized protein component and might be partly involved in estrogen action. Then, the effects of glabridin on the TNF-α-induced apoptosis and production of prostaglandin E
2 (PGE
2) and nitric oxide (NO) in osteoblasts were examined. Treatment with glabridin (1–10
μM) prevented apoptosis induced by TNF-α (10
−10
M) in osteoblastic cells. Moreover, glabridin (50
μM) decreased the 10
−10
M TNF-α-induced production of PGE
2 and NO in osteoblasts. Our data indicate that the enhancement of osteoblast function by glabridin may result in the prevention for osteoporosis and inflammatory bone diseases. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0006-2952 1873-2968 |
DOI: | 10.1016/j.bcp.2005.04.019 |